TD Cowen analyst Marc Frahm has maintained their bullish stance on JANX stock, giving a Buy rating today.
Marc Frahm has given his Buy rating due to a combination of factors including the promising clinical data from Janux Therapeutics’ ongoing trials. The company’s lead program, JANX007, has demonstrated a 100% PSA50 response rate and a median progression-free survival (mPFS) of 7.9 months at the target doses, which are considered superior to competing therapies.
Additionally, the tolerability profile of JANX007 is favorable, with minimal severe adverse effects reported. The ongoing Phase Ib trial in taxane-naive patients and the anticipated data updates from the ‘007/’008 programs further support the potential of Janux’s platform. These factors collectively underpin the Buy rating, reflecting confidence in the company’s clinical progress and future prospects.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of JANX in relation to earlier this year.